Literature DB >> 18395915

Intraperitoneal administration of gonadotropin-releasing hormone-PE40 induces castration in male rats.

Li Yu1, Zhong-Fang Zhang, Chun-Xia Jing, Feng-Lin Wu.   

Abstract

AIM: To evaluate the long-term effects of gonadotropinreleasing hormone (GnRH)-based vaccine on levels of GnRH antibody and testosterone, and vaccine-induced immunocastration on sexual behavior of male rats.
METHODS: The rats were treated with GnRH-PE40 intraperitoneally every other day for 12 wk. GnRH antibody and testosterone level in rat blood were determined by ELISA and radioimmunoassay, respectively. Morphological changes in testes and sexual behavior of rats were evaluated.
RESULTS: GnRH-PE40 induced a high production in GnRH antibody, decreased the serum testosterone level, testis atrophy and sexual function in rats.
CONCLUSION: Intraperitoneal administration of GnRHPE40 produces structural and functional castration of male rat reproductive system by inducing anti-GnRH antibody.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395915      PMCID: PMC2701535          DOI: 10.3748/wjg.14.2106

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Vaccination of boars with a GnRH vaccine (Improvac) eliminates boar taint and increases growth performance.

Authors:  F R Dunshea; C Colantoni; K Howard; I McCauley; P Jackson; K A Long; S Lopaticki; E A Nugent; J A Simons; J Walker; D P Hennessy
Journal:  J Anim Sci       Date:  2001-10       Impact factor: 3.159

Review 2.  Recent advances in contraceptive vaccine development: a mini-review.

Authors:  Rajesh K Naz; Satish K Gupta; Jagdish C Gupta; Hemant K Vyas; And G P Talwar
Journal:  Hum Reprod       Date:  2005-08-19       Impact factor: 6.918

Review 3.  Pathologic effects of testosterone deprivation.

Authors:  Preston C Sprenkle; Harry Fisch
Journal:  Curr Opin Urol       Date:  2007-11       Impact factor: 2.309

Review 4.  Drug-targeting strategies in cancer therapy.

Authors:  P S Huang; A Oliff
Journal:  Curr Opin Genet Dev       Date:  2001-02       Impact factor: 5.578

5.  Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.

Authors:  Stefanie Fister; Andreas R Günthert; Günter Emons; Carsten Gründker
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

6.  Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo.

Authors:  William Hansel; Fred Enright; Carola Leuschner
Journal:  Mol Cell Endocrinol       Date:  2006-11-13       Impact factor: 4.102

Review 7.  Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy.

Authors:  A Nagy; A V Schally
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

8.  Long-term effect of vaccination against gonadotropin-releasing hormone, using Improvac, on hormonal profile and behaviour of male pigs.

Authors:  Galia Zamaratskaia; Lotta Rydhmer; H Kristina Andersson; Gang Chen; Séverine Lowagie; Kjell Andersson; Kerstin Lundström
Journal:  Anim Reprod Sci       Date:  2007-07-10       Impact factor: 2.145

9.  Immunological hormone atrophy by gonadotropin-based drug.

Authors:  Jun Li; Jinkun Zhang
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 2.793

10.  A recombinant protein LHRH-PE40 for tumour therapy: preclinical safety studies.

Authors:  Jun Li; Yunxia Sun; Jinkun Zhang
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-12       Impact factor: 3.688

View more
  1 in total

Review 1.  New frontiers in nonhormonal male contraception.

Authors:  C Yan Cheng; Dolores D Mruk
Journal:  Contraception       Date:  2010-05-06       Impact factor: 3.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.